

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-39 (previously canceled)

Claims 40-42 (canceled)

43. (new) A method of detecting 1) one or more antibodies to HIV selected from the group consisting of antibody to HIV-1 envelope and antibody to HIV-2 envelope, and 2) one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen, in a test sample suspected of containing said one or more of said antibodies and one or more of said antigens, comprising the steps of:

a) contacting said test sample with at least one HIV-1 or HIV-2 envelope antigen for a time and under conditions sufficient for the formation of HIV-1 or HIV-2 envelope antigen/HIV-1 or HIV-2 antibody complexes;

b) adding a conjugate to the resulting HIV-1 or HIV-2 envelope antigen/HIV-1 or HIV-2 antibody complexes for a time and under conditions sufficient to allow said conjugate to bind to the bound HIV-1 or HIV-2 antibody, wherein said conjugate comprises at least one HIV-1 or HIV-2 envelope antigen for said HIV-1 or HIV-2 antibody attached to a signal generating compound capable of generating a detectable signal;

c) detecting antibody to HIV-1 or HIV-2 envelope antigen which may be present in said test sample by detecting a signal generated by said signal generating compound, presence of said signal indicating presence of antibody to HIV-1 or HIV-2 envelope antigen in said test sample;

d) contacting said test sample with at least one monoclonal antibody selected from the group consisting of 120A-270 produced by the cell line having A.T.C.C. Deposit No. PTA-3890, 115B-151 produced by the cell line having A.T.C.C. Deposit No. PTA-2809, 117-289 produced by the cell line having A.T.C.C. Deposit No. PTA-2806, 103-350 produced by the cell line having A.T.C.C. Deposit No. PTA-2808, 115B-303 produced by the cell line having A.T.C.C. Deposit No. PTA-2810 and 108-394 produced

by the cell line having A.T.C.C. Deposit No. PTA-2807 which bind to one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen for a time and under conditions sufficient for the formation of antibody/HIV-1 p24 or HIV-2 p26 core antigen complexes;

e) adding a conjugate to the resulting antibody/ HIV-1 p24 or HIV-2 p26 core antigen complexes for a time and under conditions sufficient to allow said conjugate to bind to the bound one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen, wherein said conjugate comprises an antibody attached to a signal generating compound capable of generating a detectable signal; and

f) detecting presence of said one or more antigens selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen which may be present in said test sample by detecting a signal generated by said signal generating compound, presence of said signal indicating presence of at least one antigen selected from the group consisting of HIV-1 p24 core antigen and HIV-2 p26 core antigen in said test sample.